Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.

What Was Tested

Researchers studied Antihypertensive Agents in this randomized controlled trial publication.

Irbesartan is renoprotective in patients with type 2 diabetes and microalbuminuria.

Therefore, the present substudy of the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study (IRMA-2) investigated the reversibility of kidney function changes after withdrawal of 2 years' antihypertensive treatment.

Who Took Part

The abstract describes 2 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Antihypertensive Agents study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Antihypertensive Agents could be set against what happens without it.

Arterial blood pressure, overnight urinary albumin excretion rate, and glomerular filtration rate (GFR) were determined repeatedly.

What Was Measured

PubMed files the paper under topics including Albuminuria, Angiotensin II, Antihypertensive Agents, Biphenyl Compounds, Blood Pressure, Diabetes Mellitus, Type 2 and Glomerular Filtration Rate.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Antihypertensive Agents in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Diabetes care), a journal based in United States.

More context: all human trials.